• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

快速测定人组蛋白去乙酰化酶 8 的缓慢结合抑制剂和失活剂的动力学常数。

Rapid Determination of Kinetic Constants for Slow-Binding Inhibitors and Inactivators of Human Histone Deacetylase 8.

机构信息

Department of Chemical Engineering and Biotechnology, University of Applied Sciences Darmstadt, Haardtring 100, 64295 Darmstadt, Germany.

出版信息

Int J Mol Sci. 2024 May 21;25(11):5593. doi: 10.3390/ijms25115593.

DOI:10.3390/ijms25115593
PMID:38891780
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11171933/
Abstract

The kinetics and mechanism of drug binding to its target are critical to pharmacological efficacy. A high throughput (HTS) screen often results in hundreds of hits, of which usually only simple IC values are determined during reconfirmation. However, kinetic parameters such as residence time for reversible inhibitors and the / ratio, which is the critical measure for evaluating covalent inactivators, are early predictive measures to assess the chances of success of the hits in the clinic. Using the promising cancer target human histone deacetylase 8 as an example, we present a robust method that calculates concentration-dependent apparent rate constants for the inhibition or inactivation of HDAC8 from dose-response curves recorded after different pre-incubation times. With these data, hit compounds can be classified according to their mechanism of action, and the relevant kinetic parameters can be calculated in a highly parallel fashion. HDAC8 inhibitors with known modes of action were correctly assigned to their mechanism, and the binding mechanisms of some hits from an internal HDAC8 screening campaign were newly determined. The oxonitriles SVE04 and SVE27 were classified as fast reversible HDAC8 inhibitors with moderate time-constant IC values of 4.2 and 2.6 µM, respectively. The hit compound TJ-19-24 and SAH03 behave like slow two-step inactivators or reversible inhibitors, with a very low reverse isomerization rate.

摘要

药物与靶标的结合动力学和机制对于药理学疗效至关重要。高通量 (HTS) 筛选通常会产生数百个命中物,其中通常仅在重新确证期间确定简单的 IC 值。然而,动力学参数,如可逆抑制剂的停留时间和 / 比值,是评估共价失活剂的关键指标,是评估命中物在临床成功机会的早期预测指标。以有前途的癌症靶标人组蛋白去乙酰化酶 8 为例,我们提出了一种稳健的方法,该方法可以从不同预孵育时间后记录的剂量反应曲线中计算出抑制或失活 HDAC8 的浓度依赖性表观速率常数。有了这些数据,就可以根据作用机制对命中化合物进行分类,并以高度并行的方式计算相关的动力学参数。具有已知作用模式的 HDAC8 抑制剂被正确分配到其作用机制中,并且还确定了内部 HDAC8 筛选活动中的一些命中化合物的结合机制。肟腈 SVE04 和 SVE27 被归类为快速可逆 HDAC8 抑制剂,其时间常数 IC 值分别为 4.2 和 2.6 µM。命中化合物 TJ-19-24 和 SAH03 表现为缓慢的两步失活剂或可逆抑制剂,其反向异构化速率非常低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948c/11171933/b3a87953e57b/ijms-25-05593-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948c/11171933/14188ab2a6f1/ijms-25-05593-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948c/11171933/591ebd15960e/ijms-25-05593-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948c/11171933/ae35865d5c21/ijms-25-05593-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948c/11171933/e3531caa858c/ijms-25-05593-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948c/11171933/b3a87953e57b/ijms-25-05593-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948c/11171933/14188ab2a6f1/ijms-25-05593-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948c/11171933/591ebd15960e/ijms-25-05593-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948c/11171933/ae35865d5c21/ijms-25-05593-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948c/11171933/e3531caa858c/ijms-25-05593-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948c/11171933/b3a87953e57b/ijms-25-05593-g005.jpg

相似文献

1
Rapid Determination of Kinetic Constants for Slow-Binding Inhibitors and Inactivators of Human Histone Deacetylase 8.快速测定人组蛋白去乙酰化酶 8 的缓慢结合抑制剂和失活剂的动力学常数。
Int J Mol Sci. 2024 May 21;25(11):5593. doi: 10.3390/ijms25115593.
2
Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine.3,4-二氢-2H-嘧啶并[1,2-c][1,3]苯并噻嗪-6-亚胺对组蛋白去乙酰化酶 8 的共价抑制作用。
Biochim Biophys Acta Gen Subj. 2019 Mar;1863(3):577-585. doi: 10.1016/j.bbagen.2019.01.001. Epub 2019 Jan 3.
3
Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design.基于配体和结构的药效团模型构建以促进新型组蛋白去乙酰化酶 8 抑制剂的设计。
Eur J Med Chem. 2010 Oct;45(10):4409-17. doi: 10.1016/j.ejmech.2010.06.024. Epub 2010 Jun 23.
4
Kinetically selective and potent inhibitors of HDAC8.HDAC8 动力学选择性和强效抑制剂。
Biol Chem. 2019 May 27;400(6):733-743. doi: 10.1515/hsz-2018-0363.
5
Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery.基于动态结构的药效团模型开发:组蛋白去乙酰化酶8(HDAC8)抑制剂发现中的一项新的有效补充。
Int J Mol Sci. 2011;12(12):9440-62. doi: 10.3390/ijms12129440. Epub 2011 Dec 19.
6
Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme.结构相似配体与组蛋白去乙酰化酶8结合的热力学为该酶高效且具有同工酶选择性抑制剂的合理设计面临的挑战提供了线索。
Biochemistry. 2014 Dec 9;53(48):7445-58. doi: 10.1021/bi500711x. Epub 2014 Nov 26.
7
Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity.基于结构的选择性组蛋白去乙酰化酶 8(HDAC8)抑制剂的设计与生物学特性及其抗神经母细胞瘤活性研究。
J Med Chem. 2017 Dec 28;60(24):10188-10204. doi: 10.1021/acs.jmedchem.7b01447. Epub 2017 Dec 15.
8
Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.强效帕比司他(panobinostat)组蛋白去乙酰化酶抑制剂衍生物的设计:提高 HDAC2 和 HDAC8 之间同工酶选择性的分子考虑。
Mol Inform. 2019 Mar;38(3):e1800080. doi: 10.1002/minf.201800080. Epub 2018 Oct 22.
9
Kinetics and thermodynamics of metal-binding to histone deacetylase 8.金属与组蛋白去乙酰化酶8结合的动力学和热力学
Protein Sci. 2015 Mar;24(3):354-65. doi: 10.1002/pro.2623. Epub 2015 Jan 13.
10
Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.组蛋白去乙酰化酶 8(HDAC8)选择性抑制作用的特征分析揭示了特定的活性位点结构和功能决定因素。
J Med Chem. 2018 Nov 21;61(22):10000-10016. doi: 10.1021/acs.jmedchem.8b01087. Epub 2018 Nov 8.

引用本文的文献

1
Computationally Guided Design, Synthesis, and Evaluation of Novel Non-Hydroxamic Histone Deacetylase Inhibitors, Based on -Trifluoroacetamide as a Zinc-Binding Group, Against Breast Cancer.基于三氟乙酰胺作为锌结合基团的新型非异羟肟酸类组蛋白去乙酰化酶抑制剂的计算辅助设计、合成及对乳腺癌的评估
Pharmaceuticals (Basel). 2025 Feb 28;18(3):351. doi: 10.3390/ph18030351.

本文引用的文献

1
Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice.靶向 HDAC6 治疗射血分数保留型心力衰竭的小鼠模型。
Nat Commun. 2024 Feb 26;15(1):1352. doi: 10.1038/s41467-024-45440-7.
2
Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase .二氟甲基-1,3,4-噁二唑类化合物是组蛋白去乙酰化酶的选择性、基于机制且本质不可逆的抑制剂。
J Med Chem. 2023 Oct 12;66(19):13821-13837. doi: 10.1021/acs.jmedchem.3c01345. Epub 2023 Oct 2.
3
Continuous enzyme activity assay for high-throughput classification of histone deacetylase 8 inhibitors.
用于组蛋白去乙酰化酶8抑制剂高通量分类的连续酶活性测定
Explor Target Antitumor Ther. 2023;4(3):447-459. doi: 10.37349/etat.2023.00144. Epub 2023 Jun 30.
4
The importance of binding kinetics and drug-target residence time in pharmacology.结合动力学和药物靶点停留时间在药理学中的重要性。
Br J Pharmacol. 2024 Nov;181(21):4103-4116. doi: 10.1111/bph.16104. Epub 2023 Jun 1.
5
HDAC11, an emerging therapeutic target for metabolic disorders.HDAC11,代谢紊乱的新兴治疗靶点。
Front Endocrinol (Lausanne). 2022 Oct 20;13:989305. doi: 10.3389/fendo.2022.989305. eCollection 2022.
6
3-Chloro-5-Substituted-1,2,4-Thiadiazoles (TDZs) as Selective and Efficient Protein Thiol Modifiers.3-氯-5-取代-1,2,4-噻二唑(TDZs)作为选择性和高效的蛋白质巯基修饰剂。
Chembiochem. 2022 Nov 4;23(21):e202200417. doi: 10.1002/cbic.202200417. Epub 2022 Sep 27.
7
Advances in covalent drug discovery.共价药物发现的进展。
Nat Rev Drug Discov. 2022 Dec;21(12):881-898. doi: 10.1038/s41573-022-00542-z. Epub 2022 Aug 25.
8
Drug Repurposing of Quisinostat to Discover Novel HDAC1 Inhibitors with Enhanced Triple-Stage Antimalarial Activity and Improved Safety.将喹西诺特进行药物重新利用,以发现具有增强的三阶段抗疟活性和更高安全性的新型组蛋白去乙酰化酶1(HDAC1)抑制剂。
J Med Chem. 2022 Mar 10;65(5):4156-4181. doi: 10.1021/acs.jmedchem.1c01993. Epub 2022 Feb 17.
9
Recent developments of HDAC inhibitors: Emerging indications and novel molecules.新型组蛋白去乙酰化酶抑制剂的研究进展:新的适应证和新的分子。
Br J Clin Pharmacol. 2021 Dec;87(12):4577-4597. doi: 10.1111/bcp.14889. Epub 2021 May 27.
10
Switching the Switch: Ligand Induced Disulfide Formation in HDAC8.切换开关:HDAC8 中的配体诱导二硫键形成。
Chemistry. 2020 Oct 15;26(58):13249-13255. doi: 10.1002/chem.202001712. Epub 2020 Sep 11.